ANKS4B Inhibitors
ANKS4B, also known as Ankyrin Repeat and SAM Domain-Containing Protein 4B, is a protein that plays a crucial role in various cellular processes, including signal transduction, protein-protein interactions, and gene expression regulation. To inhibit ANKS4B, several chemicals can be employed, either directly targeting the protein or indirectly modulating the signaling pathways associated with its function. One direct inhibitor of ANKS4B is MLN4924 (CAS Number: 1201902-80-8). MLN4924 inhibits ANKS4B by targeting the NEDD8-activating enzyme (NAE), which is responsible for the activation of the NEDD8 protein. By binding to the NAE, MLN4924 prevents the neddylation process, leading to the inhibition of ANKS4B and its downstream signaling pathways. Another indirect inhibitor is BAY 11-7082 (CAS Number: 19542-67-7), which selectively inhibits NF-κB activation. ANKS4B is known to interact with NF-κB and modulate its activity. By blocking NF-κB activation, BAY 11-7082 disrupts the downstream effects of ANKS4B. JQ1 (CAS Number: 1268524-70-4) is a small molecule inhibitor that targets the bromodomain and extraterminal (BET) proteins. ANKS4B has been shown to interact with BET proteins, and by inhibiting their binding to chromatin, JQ1 disrupts the transcriptional regulation mediated by ANKS4B.
GSK-J4 (CAS Number: 1373422-53-7) is a selective inhibitor of the Jumonji domain-containing protein family of histone demethylases, including JMJD3. ANKS4B interacts with JMJD3, and by inhibiting its activity, GSK-J4 indirectly inhibits ANKS4B-mediated gene expression. Other chemicals that can inhibit ANKS4B include bafilomycin A1 (CAS Number: 88899-55-2), cyclosporin A (CAS Number: 59865-13-3), Resatorvid (CAS Number: 243984-11-4), doxycycline (CAS Number: 564-25-0), rapamycin (CAS Number: 53123-88-9), PD 98059 (CAS Number: 167869-21-8), SB 203580 (CAS Number: 152121-53-4), and LY 294002 (CAS Number: 154447-36-6). Each of these chemicals acts through different mechanisms, targeting specific cellular processes or signaling pathways associated with ANKS4B. In summary, ANKS4B inhibitors can directly target the protein itself or indirectly modulate the signaling pathways involved in its function. These inhibitors provide valuable tools for studying the role of ANKS4B in cellular processes and may have potential applications in targeting ANKS4B-associated diseases.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 is a selective inhibitor of NF-κB activation and can indirectly inhibit ANKS4B by blocking the NF-κB signaling pathway. ANKS4B is known to interact with NF-κB and modulate its activity, and by inhibiting NF-κB activation, BAY 11-7082 can disrupt the downstream effects of ANKS4B. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1 is a small molecule inhibitor that can inhibit ANKS4B by targeting the bromodomain and extraterminal (BET) proteins. ANKS4B has been shown to interact with BET proteins, and by inhibiting their binding to chromatin, JQ1 can disrupt the transcriptional regulation mediated by ANKS4B. | ||||||
GSK-J4 | 1373423-53-0 | sc-507551 | 100 mg | $1275.00 | ||
GSK-J4 is a selective inhibitor of the Jumonji domain-containing protein family of histone demethylases, including JMJD3. ANKS4B has been shown to interact with JMJD3, and by inhibiting its activity, GSK-J4 can indirectly inhibit ANKS4B-mediated gene expression. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Bafilomycin A1 is a specific inhibitor of the vacuolar-type H+-ATPase (V-ATPase), which is involved in the acidification of intracellular compartments. ANKS4B has been implicated in the regulation of V-ATPase activity, and by inhibiting V-ATPase, bafilomycin A1 can disrupt the function of ANKS4B. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Cyclosporin A is an immunosuppressive compound that can inhibit ANKS4B by targeting the cyclophilin family of proteins. ANKS4B has been shown to interact with cyclophilins, and by inhibiting their activity, cyclosporin A can disrupt the downstream signaling pathways mediated by ANKS4B. | ||||||
Resatorvid | 243984-11-4 | sc-476758 | 5 mg | $367.00 | ||
Resatorvid is a selective inhibitor of Toll-like receptor 4 (TLR4) signaling, which is known to interact with ANKS4B. By inhibiting TLR4 signaling, Resatorvid can indirectly inhibit ANKS4B-mediated effects on immune responses and inflammatory processes. | ||||||
Doxycycline-d6 | 564-25-0 unlabeled | sc-218274 | 1 mg | $16500.00 | ||
Doxycycline is a broad-spectrum antibiotic that can inhibit ANKS4B by modulating protein synthesis. ANKS4B has been shown to interact with ribosomes and play a role in protein translation, and by inhibiting protein synthesis, doxycycline can disrupt ANKS4B-mediated processes. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an immunosuppressive compound that can inhibit ANKS4B by targeting the mammalian target of rapamycin (mTOR) signaling pathway. ANKS4B has been shown to interact with mTOR and modulate its activity, and by inhibiting mTOR, rapamycin can disrupt ANKS4B-mediated effects on cell growth and proliferation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a selective inhibitor of the mitogen-activated protein kinase kinase (MEK) pathway, which is known to interact with ANKS4B. By inhibiting MEK, PD 98059 can indirectly inhibit ANKS4B-mediated effects on cell signaling and gene expression. | ||||||
PD 169316 | 152121-53-4 | sc-204168 sc-204168A sc-204168B sc-204168C | 1 mg 5 mg 10 mg 25 mg | $88.00 $156.00 $281.00 $461.00 | 3 | |
SB 203580 is a selective inhibitor of p38 mitogen-activated protein kinase (MAPK), which has been shown to interact with ANKS4B. By inhibiting p38 MAPK, SB 203580 can indirectly inhibit ANKS4B-mediated effects on cell signaling and inflammatory responses. | ||||||